Avistone’s next-gen ROS1/NTRK TKI cleared to enter clinic for advanced tumors
Dec. 5, 2024
Beijing Avistone Biotechnology Co. Ltd. has obtained IND clearance from the FDA for ANS-03, a next-generation tyrosine kinase inhibitor (TKI) targeting both ROS proto-oncogene 1 (ROS1) and neurotrophic tropomyosin receptor kinase (NTRK).